HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme
Help Login Register
Market News Stocks News ETF News Crypto News

Intellia Therapeutics, Inc.

Contributing Author

Recent Articles by Intellia Therapeutics, Inc.

Jun-15
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress NTLA GlobeNewswire
Jun-05
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
May-18
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting NTLA GlobeNewswire
May-08
Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress NTLA GlobeNewswire
May-06
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Affiliate • Advertise • Theme Settings • Contact • Help • Privacy • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.

Learn more about FINVIZ*Elite